Socma Testifies on Risks Involving Pharma Ingredient Imports

Socma’s bulk pharmaceutical task force chief John Dubeck testified last week at a House Energy & Commerce Committee’s subcommittee on oversight and investigation about risks associated with drugs imported into the U.S. There is a lack of government inspections of overseas facilities manufacturing active pharma ingredients (APIs) that go into drugs, Dubeck says. The majority of overseas facilities manufacturing APIs used in generic medications rarely see an FDA inspector after an initial inspection, and most overseas manufacturers of...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers